Vaxcyte (PCVX) to Release Earnings on Tuesday

Vaxcyte (NASDAQ:PCVX) is anticipated to post its quarterly earnings results after the market closes on Tuesday, February 25th. Analysts expect Vaxcyte to post earnings of ($1.16) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Vaxcyte Price Performance

Vaxcyte stock opened at $79.74 on Friday. The stock has a market capitalization of $9.94 billion, a price-to-earnings ratio of -17.33 and a beta of 0.98. Vaxcyte has a 1-year low of $58.10 and a 1-year high of $121.06. The business has a fifty day moving average price of $85.61 and a 200-day moving average price of $94.76.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $14.00 price objective on shares of Vaxcyte in a research report on Tuesday, February 11th. The Goldman Sachs Group assumed coverage on Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $127.71.

Insiders Place Their Bets

In other news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $92.45, for a total value of $1,386,750.00. Following the completion of the transaction, the chief executive officer now owns 450,301 shares of the company’s stock, valued at $41,630,327.45. The trade was a 3.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total value of $710,240.00. Following the completion of the transaction, the chief financial officer now directly owns 109,491 shares of the company’s stock, valued at approximately $9,720,610.98. This trade represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 76,616 shares of company stock valued at $6,766,481. 3.10% of the stock is owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.